Earnings Feed
Start Free
Home/Filings/4/0001077183-25-000016
4//SEC Filing

Olivo Alicia C 4

Accession 0001077183-25-000016

CIK 0001077183other
View on SEC.govCompany Profile

Filed

Jan 15, 7:00 PM ET

Accepted

Jan 16, 4:11 PM ET

Size

24.4 KB

Accession

0001077183-25-000016

Insider Transaction Report

Form 4
Period: 2025-01-14
NEOGENOMICS INCNEO
Olivo Alicia C
EVP, GC & Business Development
Transactions
  • Award

    Restricted Stock Unit

    2025-01-14+59,382→ 59,382 total
    Exercise: $0.00From: 2026-01-13→ Common Stock (59,382 underlying)
Holdings

  • Stock Option (Right to Buy)

    Exercise: $27.34Exp: 2027-05-01→ Common Stock (1,024 underlying)
    1,024

  • Stock Option (Right to Buy)

    Exercise: $48.99Exp: 2028-05-01→ Common Stock (516 underlying)
    516

  • Restricted Stock Unit

    Exercise: $0.00→ Common Stock (13,006 underlying)
    13,006

  • Restricted Stock Unit

    Exercise: $0.00→ Common Stock (25,329 underlying)
    25,329

  • Common Stock

    39,414

  • Stock Option (Right to Buy)

    Exercise: $46.10Exp: 2028-08-01→ Common Stock (1,117 underlying)
    1,117

  • Stock Option (Right to Buy)

    Exercise: $9.45Exp: 2029-05-01→ Common Stock (22,222 underlying)
    22,222

  • Stock Option (Right to Buy)

    Exercise: $19.65Exp: 2030-05-11→ Common Stock (36,508 underlying)
    36,508

  • Stock Option (Right to Buy)

    Exercise: $16.45Exp: 2034-02-23→ Common Stock (42,344 underlying)
    42,344

  • Performance Stock Unit

    Exercise: $0.00From: 2026-05-11→ Common Stock (19,508 underlying)
    19,508

  • Stock Option (Right to Buy)

    Exercise: $19.12Exp: 2026-09-30→ Common Stock (1,046 underlying)
    1,046

  • Stock Option (Right to Buy)

    Exercise: $10.05Exp: 2029-09-01→ Common Stock (55,332 underlying)
    55,332

  • Performance Stock Unit

    Exercise: $0.00From: 2027-02-23→ Common Stock (25,330 underlying)
    25,330
Footnotes (14)
  • [F1]This balance includes 503 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan ("ESPP"). The shares were acquired in transactions exempt from Section 16b-3. A Form 4 filed on August 5, 2024 included a footnote with reference to 378 ESPP shares having been acquired and a Form 4 filed on August 19, 2024 included a footnote with reference to 125 ESPP shares having been acquired, however those shares were inadvertently not reflected in the balance in Column 5 on those Form 4s. Those shares are now reflected in this balance.
  • [F10]On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
  • [F11]On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F12]On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F13]On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
  • [F14]On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F2]Once vested, the shares of common stock are not subject to expiration.
  • [F3]On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
  • [F4]On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F5]On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F6]On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F7]On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F8]On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F9]On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.

Documents

1 file

Issuer

NEOGENOMICS INC

CIK 0001077183

→
Entity typeother

Related Parties

1
  • filerCIK 0001951869

Filing Metadata

Form type
4
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 4:11 PM ET
Size
24.4 KB
View on SEC.gov